#311 - Can Your Blood Predict Your Future Health? | Dr. Tony Wyss-Coray & Mike Haney
LEVELS – A Whole New LevelShow Notes
From a single blood sample, new proteomic tools can now measure thousands of proteins at once. Dr. Tony Wyss-Coray’s lab is using that flood of data, together with machine learning, to build a much higher-resolution picture of what’s happening throughout the body and where someone’s health may be headed.
The early signals are striking. In one analysis of people who appeared healthy by conventional measures, every additional 4.1 years of estimated heart age was associated with nearly 2.5 times the risk of heart failure over the following 15 years. Wyss-Coray sees this kind of measurement eventually becoming a “health compass”: something that could show which parts of the body are changing fastest, then help track whether an intervention is actually moving them in the right direction.
Free course: Improve your metabolic health Get our free email course on how glucose, nutrition, exercise, sleep, and measurement can help you build habits that support better energy and long-term health: https://levels.link/wnl
What We Cover: How a drop of blood can now reveal information from thousands of proteins Why aging appears to happen in waves rather than at a steady rate Why one part of the body may age faster than the rest What young-blood experiments in mice taught Wyss-Coray about proteins and brain aging How the work is moving from whole organs down to individual cell types Why the field’s biggest constraint may now be data collection rather than better AI
🎙️ About the Guest: Dr. Tony Wyss-Coray is the D.H. Chen Distinguished Professor of Neurology and Neurological Sciences at Stanford University and director of the Phil and Penny Knight Initiative for Brain Resilience.
📍What Dr. Tony Wyss-Coray & Mike Haney discussed: 04:03 Proteins 101: the building blocks hiding information about your health 05:09 How one blood sample can measure thousands of proteins 09:07 Using machine learning to find patterns in the proteome 12:17 Can blood reveal what’s happening inside the brain? 13:11 What happened when young blood was given to old mice 19:45 Why aging may happen in waves rather than at a steady rate 29:24 How stable are protein measurements over time? 32:37 Can proteins predict disease years before it appears? 40:35 Why one part of your body may age faster than the rest 46:31 The missing test: does an intervention actually change the measurement? 51:04 Going from whole organs to individual cell types 54:10 Why more data, not better AI, is the current bottleneck 57:18 A future “health compass” for the body
🔗 Helpful Links: Organ aging signatures in the plasma proteome track health and disease (Nature, 2023)Paper The foundational organ-aging work discussed in the episode, using plasma proteins to estimate aging across 11 organs. Plasma proteomic signatures of cellular aging predict human disease (Nature Medicine, 2026)Paper The newer study extending the approach to more than 40 cell types using over 7,000 plasma proteins. Undulating changes in human plasma proteome profiles across the lifespan (Nature Medicine, 2019)Paper
Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice (Nature Medicine, 2014)Paper
UK Biobank Research resource The large longitudinal cohort used for much of the disease-prediction work discussed in the episode.
Watch the conversation: https://youtu.be/1dfMBAZiP8o Find us on YouTube: https://youtube.com/levelshealth?sub_confirmation=1
📲 Connect: Connect with Dr. Tony Wyss-Coray at Stanford
👋 Who we are: Levels helps you understand your metabolic health with personalized data, expert guidance, and tools that connect your daily choices to measurable changes in your body. Our goal is to help you make better decisions about food, exercise, sleep, and long-term health.
Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.
More from LEVELS – A Whole New Level
Heart disease is the leading cause of death, but it’s also one of the most preventable. Decades of research have established a strong causal role for LDL and other ApoB-containing particles in atherosclerosis, and we now have multiple proven ways to lower them. The harder question is how to turn that evidence into a decision for an individual person. Mike Haney talks with Johns Hopkins cardiologist Dr. Seth Martin, a co-author of the new 2026 dyslipidemia guidelines, about what the latest evidence says we should actually measure and act on. The throughline is pragmatic: lower exposure to atherogenic particles earlier and for longer, use additional tests when they can change a decision, and distinguish interesting new measurements from ones that have actually been shown to improve outcomes.
Most of NextLevel starts with a measurement problem: we can see more biology than ever, but we still have to figure out what to do with it. Bioelectronic medicine flips that sequence. We already know how to send electrical signals into the nervous system to change biology, including an FDA-approved vagus nerve treatment for rheumatoid arthritis, even though we still can’t map or read most of the individual nerve fibers carrying those signals.
Most health decisions happen before the science is settled. A study points one way, another points somewhere else, experts disagree about what matters, and even strong population-level evidence may not tell you what will happen to you.
Most medical imaging happens after a symptom, injury, or abnormal test gives a clinician a reason to look. But what changes if imaging becomes a more routine measurement, creating a record of the body before something goes wrong? In this episode of Next Level, Mike Haney talks with Dr. Daniel Durand, chief medical officer at Prenuvo, about whole-body MRI as a test case for a broader shift from episodic medicine toward longitudinal health data. Whole-body MRI is controversial, and Durand is clearly an advocate. The conversation takes the skepticism seriously, then asks a larger question: as measurement gets cheaper, more frequent, and increasingly visible to patients themselves, how should medicine decide what is worth knowing?
Alcohol has spent the last 40 years bouncing between two health narratives: a little is good for your heart, or any amount is dangerous. The science doesn’t really support either slogan. Dr. Tim Naimi has spent decades studying the health effects of alcohol and, just as importantly, why the research is so difficult to interpret. His read of the evidence is less dramatic but more useful: there’s no good reason to start drinking for your health, very low intake may carry little measurable added risk, and risk rises as consumption does. Understanding why earlier studies made moderate drinking look protective helps explain a lot of the whiplashing headlines.